<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="726">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151705</url>
  </required_header>
  <id_info>
    <org_study_id>HR17031-103</org_study_id>
    <nct_id>NCT05151705</nct_id>
  </id_info>
  <brief_title>A Trial of HR17031 Injection With Hepatic Insufficiency</brief_title>
  <official_title>Pharmacokinetics and Safety of HR17031 Injection in Subjects With Mild and Moderate Liver Impairment and Normal Liver Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study used a single-dose, open design to compare the pharmacokinetics of subjects with&#xD;
      mild and moderate liver impairment and subjects with normal liver function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Compare the pharmacokinetics of HR17031 injection in subjects with mild and moderate liver impairment and normal liver function</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: Cmax</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: Tmax</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: T1/2</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: CL/F</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of INS068 and SHR20004: Vz/F</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding rate of plasma protein of INS068 in serum and SHR20004 in plasma(fu)</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of adverse events/serious adverse events</measure>
    <time_frame>Based on pre-dose, 2-96 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic：Serum c-peptide</measure>
    <time_frame>Based on pre-dose, 8-24 hours post-dose sampling times</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Improved Glycemic Control in Patients With Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment group A: HR17031 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B: HR17031 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C: HR17031 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection</intervention_name>
    <description>Treatment group A:HR17031 injection; 10U/0.024mg</description>
    <arm_group_label>Treatment group A: HR17031 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection</intervention_name>
    <description>Treatment group B: HR17031 injection; 10U/0.024mg</description>
    <arm_group_label>Treatment group B: HR17031 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR17031 injection</intervention_name>
    <description>Treatment group C: HR17031 injection; 10U/0.024mg</description>
    <arm_group_label>Treatment group C: HR17031 injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent before the test, and fully understood the test content,&#xD;
             process and possible adverse reactions; And able to complete the research according to&#xD;
             the requirements of the test protocol;&#xD;
&#xD;
          2. Subject (including partner) is willing to voluntarily take effective contraceptive&#xD;
             measures within 10 weeks from screening to the last study drug administration. For&#xD;
             specific contraceptive measures, see Appendix 1;&#xD;
&#xD;
          3. Age 18-65 (including threshold), male and female;&#xD;
&#xD;
          4. The weight of male subjects should not be less than 50 kg, and that of female subjects&#xD;
             should not be less than 45 kg. Body mass index (BMI) : 18~32 kg/m2 (including critical&#xD;
             value);&#xD;
&#xD;
          5. For subjects with normal liver function, normal or abnormal clinical laboratory tests&#xD;
             (blood routine, blood biochemistry, urine routine, coagulation function) have no&#xD;
             clinical significance;&#xD;
&#xD;
          6. Subjects with normal liver function: no previous serious primary diseases of important&#xD;
             organs, including but not limited to gastrointestinal, respiratory, kidney, liver,&#xD;
             nervous, blood, endocrine, tumor, immune, mental or cardiovascular diseases.&#xD;
&#xD;
             For subjects with impaired liver function, the following inclusion criteria should&#xD;
             also be met:&#xD;
&#xD;
          7. Those who have not taken medication within 4 weeks prior to screening, or who require&#xD;
             long-term treatment for liver damage and/or other comorbidities, have taken stable&#xD;
             medication for at least 4 weeks;&#xD;
&#xD;
          8. Patients with child-Pugh grade A or B hepatic dysfunction resulting from previous&#xD;
             primary liver disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic disposition, or known or suspected allergy to any of the ingredients in the&#xD;
             study drug;&#xD;
&#xD;
          2. Smoked more than 5 cigarettes per day on average within 3 months before screening;&#xD;
&#xD;
          3. Average daily alcohol intake in the 3 months prior to screening exceeds the following&#xD;
             criteria: 15g (e.g., 145 mL wine, 497 mL beer or 43 mL low-alcohol liquor) for women&#xD;
             and 25g (e.g., 290 mL wine, 994 mL beer or 86mL low-alcohol liquor) for men;&#xD;
&#xD;
          4. A history of drug abuse within 3 months prior to the screening period;&#xD;
&#xD;
          5. Those who donated blood or lost blood ≥400 mL or received blood transfusion within 3&#xD;
             months prior to screening;&#xD;
&#xD;
          6. Major surgery or surgical incision not completely healed within 6 months prior to&#xD;
             screening;&#xD;
&#xD;
          7. Taking Chinese herbal medicine within 2 weeks before administration;&#xD;
&#xD;
          8. Have a malignant tumor, or have a history of malignant tumor in the 5 years prior to&#xD;
             screening (excluding treated skin non-melanoma with no signs of recurrence, and&#xD;
             excised cervical intraepithelial neoplasia);&#xD;
&#xD;
          9. Systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 100 mmHg at screening&#xD;
             time;&#xD;
&#xD;
         10. Female subjects are lactating or have positive serum pregnancy results during the&#xD;
             screening period or during the test;&#xD;
&#xD;
         11. For subjects with normal liver function: participants in clinical trials of any drug&#xD;
             or medical device within 3 months prior to screening; For subjects with impaired liver&#xD;
             function: participants in clinical trials of any drug or medical device within 1 month&#xD;
             prior to screening;&#xD;
&#xD;
         12. Patients whose ECG abnormality is clinically significant (e.g.,&#xD;
             tachycardia/bradycardia requiring medical treatment, degree II-III ATrioventricular&#xD;
             block, or prolonged QTcF interval (males ≥470 ms, females ≥480 ms) (corrected&#xD;
             according to Fridericia's formula) and determined by clinicians to be unsuitable for&#xD;
             this study;&#xD;
&#xD;
         13. Creatinine clearance (CLcr, calculated by Cockcroft-Gault formula, Appendix III) ≤60&#xD;
             mL/min;&#xD;
&#xD;
         14. Subjects with normal liver function: those who are positive for hepatitis B surface&#xD;
             antigen, hepatitis C antibody or hepatitis C core antigen, HIV antibody or syphilis&#xD;
             antibody screened are excluded;&#xD;
&#xD;
         15. Screening for positive urine drugs (morphine, cannabis);&#xD;
&#xD;
         16. Within 1 day before administration, those who have eaten any food or drink containing&#xD;
             alcohol (or positive breath test for alcohol), grapefruit juice/grapefruit juice,&#xD;
             methylxanthine (such as coffee, tea, cola, chocolate, energy drink), strenuous&#xD;
             exercise or other factors affecting drug absorption, distribution, metabolism,&#xD;
             excretion, etc.;&#xD;
&#xD;
         17. Patients who are expected to be prone to surgery or hospitalization during the study&#xD;
             period;&#xD;
&#xD;
         18. Any factors that the investigator considers inappropriate for participation in this&#xD;
             study.&#xD;
&#xD;
             Supplementary exclusion criteria for subjects with liver function impairment&#xD;
             (exclusion if meeting 1 of these criteria) :&#xD;
&#xD;
         19. History of liver transplantation;&#xD;
&#xD;
         20. Subjects with liver failure or cirrhosis with hepatic encephalopathy, hepatocellular&#xD;
             carcinoma, esophageal and gastric variceal hemorrhage and other complications deemed&#xD;
             unsuitable for the study by the investigator;&#xD;
&#xD;
         21. In addition to the primary liver disease itself, has a history of any serious illness,&#xD;
             or history of researchers think that may affect the test results and/or anomalies have&#xD;
             clinical significance of clinical laboratory tests, including but not limited to the&#xD;
             circulatory system, endocrine system, nervous system, digestive system, urinary&#xD;
             system, or blood, immune, spirit and metabolic disease.&#xD;
&#xD;
         22. HIV antibody screening positive; If syphilis antibody is positive, rapid plasma&#xD;
             rereaction test (RPR) should be added. If RPR is positive at the same time, it should&#xD;
             be excluded.&#xD;
&#xD;
         23. Alpha-fetoprotein &gt; 50 ng/mL; Or neutrophil count (ANC) ≥0.75×109/L (1,500/mm3); Or&#xD;
             Hgb ≤7.0 g/dL (90 g/L); Or ALT and AST ≥10 times the upper limit of normal (ULN) were&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng Feng, Ph.D.</last_name>
    <phone>13817253036</phone>
    <email>Sheng.feng@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxiong Gao, Ph.D.</last_name>
    <phone>19821262236</phone>
    <email>gaoyu.xiong@hengrui.cn</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

